Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients.

ABSTRACT:

Background

Although metastatic breast cancer (MBC) remains incurable, advances in therapies have improved survival. Using a contemporary dataset of de novo MBC patients, we explore how overall (OS) and cancer-specific survival (CSS) changed over time.

Methods

All patients with de novo MBC from 1988 to 2016 were selected from Surveillance, Epidemiology, and End Results (SEER) 18. Unadjusted OS and CSS were estimated by Kaplan-Meier method and stratified by disease characteristics. Cox proportional hazards models determined factors associated with survival.

Results

47,034 patients were included, with median OS of 25 months and CSS of 27 months. Survival steadily improved over time (1988: 1-year OS 62%, CSS 65%; 2015: 1-year OS 72%, CSS 74%). Patients with triple-negativ

SUBMITTER: Taskindoust M 

PROVIDER: S-EPMC8530869 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature